Phase I Trial of Intensity-Modulated Hyperfractionated Radiotherapy Boost with Concurrent Chemotherapy Immediately Following Standard Chemoradiotherapy in Advanced Esophageal Cancer.
Local persistence and relapse of disease in the gross tumor volume (GTV) account for the majority of treatment failures after standard chemoradiotherapy. The primary objective of this phase I trial was to define the maximum tolerated dose (MTD) of a hyperfractionated radiation therapy (HFRT) boost to GTV with concurrent weekly paclitaxel and carboplatin following standard-dose chemoradiotherapy, using image-guided intensity-modulated radiotherapy (IGMRT) techniques. Eligible patients were given weekly doses of paclitaxel (45 mg/m2) and carboplatin AUC 1.5 for 5 weeks with concurrent RT (50 Gy), immediately followed by HFRT boost to GTV with the same chemotherapy regimen. The boost doses were escalated in increments of 7.2 Gy delivered in 6 twice daily fractions of 1.2 Gy using a modified Fibonacci design. Once the MTD was established, additional patients were treated at that dose to determine the safety. Thirty-one patients fulfilled the inclusion criteria. The incidence of dose-limiting toxicity (DLT) was 0/3, 0/3, 0/3, 1/6 (grade 4 esophagitis), 0/3, 2/3 (1 case each of grade 5 esophageal fistula and grade 3 pneumotitis) at 7.2, 14.4, 21.6, 28.8, 36 and 43.2 Gy respectively, indicating an MTD of 36 Gy. Ten patients treated with this MTD showed no DLTs. The most common acute grade 3 or greater toxicities were esophagitis (26%) and neutropenia (19%). Late toxicity of grade 2 esophageal stricture occurred in four patients. The overall response rate was 84% (95% CI, 42% to 93%) in the entire cohort. The 1-year local control rate was 100% among those receiving a cumulative dose of the MTD or greater. The MTD of the HFRT boost following standard chemoradiotherapy in the setting of concurrent chemotherapy was 36 Gy, resulting in the cumulative tumor dose of 86 Gy in patients primarily with advanced intra-thoracic/cervical esophageal squamous cell carcinomas and not adenocarcinomas of the gastroesophageal junction. A phase II study to further evaluate this regimen is underway.